Johnson & Johnson to Acquire Proteologix for $850 Million, Expanding its Portfolio of Atopic Dermatitis Treatments

Johnson & Johnson has announced its plans to acquire Proteologix, Inc. for $850 million in cash, with the potential for an additional milestone payment. The acquisition is expected to be finalized by mid-year 2024, pending antitrust clearance and other customary closing conditions.

The deal includes Proteologix's portfolio of experimental atopic dermatitis treatments, including PX128 and PX130, both of which target different pathways in the treatment of moderate to severe atopic dermatitis  and moderate to severe asthma. This move aligns with J&J's commitment to expanding its reach and impact for people living with immune-mediated diseases, leveraging more targeted options to achieve durable, symptom-free remission.

The acquisition of Proteologix will not only expand J&J's portfolio of atopic dermatitis treatments but also provide the company with other bispecific antibody programs applicable to various diseases, strengthening its capabilities in creating novel bispecific programs.